CA2517456A1 - Shivering suppression during cooling to lower body temperature - Google Patents
Shivering suppression during cooling to lower body temperature Download PDFInfo
- Publication number
- CA2517456A1 CA2517456A1 CA002517456A CA2517456A CA2517456A1 CA 2517456 A1 CA2517456 A1 CA 2517456A1 CA 002517456 A CA002517456 A CA 002517456A CA 2517456 A CA2517456 A CA 2517456A CA 2517456 A1 CA2517456 A1 CA 2517456A1
- Authority
- CA
- Canada
- Prior art keywords
- human
- shivering
- drug
- transferring
- heat transfer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Active cooling of a person, such as to induce mild/moderate hypothermia, is accomplished by transferring heat from the persons body. Heat transfer and patient comfort are aided by administartion of an anti-shivering drug and an anti-emetic drug.
Description
SHIVERING SUPPRESSION DURING COOLING
TO LOWER BODY TEMPERATURE
FIELD OF THE INVENTION
The invention relates to active cooling of the human body for therapeutic puyoses, such as to induce hypothermia in people suffering a condition involving reduced blood supply.
BACKGROUND OF THE INVENTION
Therapeutic induced mild-moderate hypothermia can be beneficial for people suffering stroke, myocardial infarction, cardiac arrest and other conditions involving reduced blood supply. One method for lowering body temperature is to insert a cooling device into an artery of the patient and to internally cool the patient's body by introducing a cooling fluid into the device. One concern for such endovascular techniques is the invasive nature of the procedure. A non-invasive technique for lowering body temperature is to externally cool the surface of the patient's body. Such exterior surface cooling could be achieved by directing the flow of a cooling fluid, such as cool air, around the patient's body. A more preferred external surface cooling technique is to apply a contact-cooling pad to the exterior surface of the patient and to circulate a cooling fluid, such as water or an aqueous solution, through the contact pad to cool the patient.
As a patient's body is cooled, shivering is likely to occur as a thermoregulatory response to the cooling. Shivering can increase heat production as much as 600% above basal levels. When shivering occurs during inducement of hypothermia, the additional heat production counteracts the active cooling of the patient's body and can significantly delay or even prevent attainment the desired lower body temperature.
An anti-shivering drug can be administered to the patient to suppress shivering during therapeutic inducement of hypothermia. Meperidine is one drug used for treatment to suppress post-operative shivering. Because conditions during induced hypothermia are much more severe than in the post-operative situation, the use of meperidine for shivering suppression during induced hypothermia may require administration of larger quantities of the drug for temperature management.
With administration of large doses of meperidine, there is a concern for possible respiratory depression and nausea and vomiting. Even when not creating a medical concern, it would be desirable to suppress nausea and vomiting for patient comfort. Also, it is normally desirable to maintain the patient as conscious and responsive as possible, to facilitate monitoring of the patient's condition, such as for indications of neural impairment.
SUMMARY OF THE INVENTION
With the invention, an anti-emetic drug may be administered in combination with administration of an anti-shivering drug for shivering suppression. The use of the anti-emetic drug may permit a level of shivering suppression to be attained with administration of a reduced quantity of the anti-shivering drug relative to use of the anti-shivering drug alone, and with reduced incidence of nausea and vomiting.
In one implementation, the invention may involve a method for lowering body temperature of a human patient, with the method involving transferring heat from the patient's body to cool the patient's body, administering an anti-emetic drug to the patient and administering an anti-shivering drug to the patient. The anti-emetic drug and the anti-shivering drug are administered in therapeutically effective quantities respectively for suppression during heat transfer of nausea and vomiting and of shivering.
The lowering of the body temperature may be for any purpose, such as for example to reduce body temperature fiom an elevated level to normal (noimothermia) in the case of fever or to reduce the body temperature to below normal (hypothermia) in the case of stroke, myocardial infarction or cardiac arrest.
The anti-shivering drug may comprise one or more substance effective for suppressing shivering. A variety of such anti-shivering drugs are known or may be identified in the future. Examples of some reported anti-shivering drugs include certain non-opioid analgesics (for example, tramodol and nefopan), certain opioid analgesics (for example, alfentanil, morphine, fentanyl, meperidine, naloxone and nalbuphine), certain a2-andrenergic agonists (for example, clonidine and dexmedetomidine) and certain serotonin antagonists (for example, ketanserin and ondansetron). Also, multiple anti-shivering drugs may be used to the extent they are pharmacologically compatible.
Moreover, it should be appreciated that drugs are often administered in the form of pharmacologically acceptable salts, so for example, the anti-shivering drug may be such a salt of any of the foregoing listed compounds. Meperidine, or a salt thereof, is particularly preferred for use as the anti-shivering drug. Unless otherwise required by the specific context, when a reference is made herein, including in the claims, to a drug compound, the reference includes the named compound and chemical variations of the named compound, and particularly includes salts of the compound, that are pharmacologically acceptable for administration to human subjects.
The anti-emetic drug is different than the anti-shivering drug, and the anti-emetic drug may comprise one or more substance effective for suppressing nausea and/or vomiting. A variety of such anti-shivering drugs are known or may be identified in the future. Examples of some anti-emetic drugs include certain DZ dopamine antagonists/blocking agents (for example, phenothiazine antipsycotics such as prochlorperazine, triflupromazine, chlorpromazine and trifluoiperazine; and metoclopramide), promethazine (both a D2 dopamine antagonist and an Hl histamine antagonist), certain antihistamines with anticholinergic effects (for example, diphenhydramine, dimenhydrinate and meclizine), and certain serotonin antagonists (for example, ondansetron, granisetron and tropisetron, which are 5-HT3 antagonists).
Preferred for use as the anti-emetic drug is one or more 5-HT3 antagonist.
Also, multiple anti-emetic drugs may be used to the extent they are pharmacologically compatible.
Moreover, as noted above, drugs are often administered in the form of pharmacologically acceptable salts, so for example, the anti-emetic drug may be such a salt of any of the foregoing listed compounds. Ondansetron, or a salt thereof, is particularly preferred for use as the anti-emetic drug.
In one preferred implementation of the invention, the anti-emetic drug comprises a 5-HT3 antagonist and the anti-shivering drug comprises an opioid analgesic. A
particularly preferred pairing is for the anti-emetic drug to comprise ondansetron, or a salt thereof, and the anti-shivering drug to comprise meperidine, or a salt thereof. In one particularly preferred implementation, the use of the anti-emetic drug in combination with the anti-shivering drug reduces the quantity of the anti-shivering drug required to treat for the shivering suppression, relative to use of the anti-shivering drug alone.
For example, an anti-emetic drug can be selected that independently acts to provide at least some level of shivering suppression. This is the case, for example, with the use of ondansetron, , which as noted above has been reported for shivering suppression.
As noted above, each of the anti-emetic drug and the anti-shivering drug should be administered in therapeutically effective quantities. By "effective quantity"
or "therapeutically effective quantity" of the anti-emetic drug and the anti-shivering drug, it is meant that the drug at issue is administered at a dose and with a dosing regimen that is pharmacologically acceptable to treat for the target condition under the circumstances.
TO LOWER BODY TEMPERATURE
FIELD OF THE INVENTION
The invention relates to active cooling of the human body for therapeutic puyoses, such as to induce hypothermia in people suffering a condition involving reduced blood supply.
BACKGROUND OF THE INVENTION
Therapeutic induced mild-moderate hypothermia can be beneficial for people suffering stroke, myocardial infarction, cardiac arrest and other conditions involving reduced blood supply. One method for lowering body temperature is to insert a cooling device into an artery of the patient and to internally cool the patient's body by introducing a cooling fluid into the device. One concern for such endovascular techniques is the invasive nature of the procedure. A non-invasive technique for lowering body temperature is to externally cool the surface of the patient's body. Such exterior surface cooling could be achieved by directing the flow of a cooling fluid, such as cool air, around the patient's body. A more preferred external surface cooling technique is to apply a contact-cooling pad to the exterior surface of the patient and to circulate a cooling fluid, such as water or an aqueous solution, through the contact pad to cool the patient.
As a patient's body is cooled, shivering is likely to occur as a thermoregulatory response to the cooling. Shivering can increase heat production as much as 600% above basal levels. When shivering occurs during inducement of hypothermia, the additional heat production counteracts the active cooling of the patient's body and can significantly delay or even prevent attainment the desired lower body temperature.
An anti-shivering drug can be administered to the patient to suppress shivering during therapeutic inducement of hypothermia. Meperidine is one drug used for treatment to suppress post-operative shivering. Because conditions during induced hypothermia are much more severe than in the post-operative situation, the use of meperidine for shivering suppression during induced hypothermia may require administration of larger quantities of the drug for temperature management.
With administration of large doses of meperidine, there is a concern for possible respiratory depression and nausea and vomiting. Even when not creating a medical concern, it would be desirable to suppress nausea and vomiting for patient comfort. Also, it is normally desirable to maintain the patient as conscious and responsive as possible, to facilitate monitoring of the patient's condition, such as for indications of neural impairment.
SUMMARY OF THE INVENTION
With the invention, an anti-emetic drug may be administered in combination with administration of an anti-shivering drug for shivering suppression. The use of the anti-emetic drug may permit a level of shivering suppression to be attained with administration of a reduced quantity of the anti-shivering drug relative to use of the anti-shivering drug alone, and with reduced incidence of nausea and vomiting.
In one implementation, the invention may involve a method for lowering body temperature of a human patient, with the method involving transferring heat from the patient's body to cool the patient's body, administering an anti-emetic drug to the patient and administering an anti-shivering drug to the patient. The anti-emetic drug and the anti-shivering drug are administered in therapeutically effective quantities respectively for suppression during heat transfer of nausea and vomiting and of shivering.
The lowering of the body temperature may be for any purpose, such as for example to reduce body temperature fiom an elevated level to normal (noimothermia) in the case of fever or to reduce the body temperature to below normal (hypothermia) in the case of stroke, myocardial infarction or cardiac arrest.
The anti-shivering drug may comprise one or more substance effective for suppressing shivering. A variety of such anti-shivering drugs are known or may be identified in the future. Examples of some reported anti-shivering drugs include certain non-opioid analgesics (for example, tramodol and nefopan), certain opioid analgesics (for example, alfentanil, morphine, fentanyl, meperidine, naloxone and nalbuphine), certain a2-andrenergic agonists (for example, clonidine and dexmedetomidine) and certain serotonin antagonists (for example, ketanserin and ondansetron). Also, multiple anti-shivering drugs may be used to the extent they are pharmacologically compatible.
Moreover, it should be appreciated that drugs are often administered in the form of pharmacologically acceptable salts, so for example, the anti-shivering drug may be such a salt of any of the foregoing listed compounds. Meperidine, or a salt thereof, is particularly preferred for use as the anti-shivering drug. Unless otherwise required by the specific context, when a reference is made herein, including in the claims, to a drug compound, the reference includes the named compound and chemical variations of the named compound, and particularly includes salts of the compound, that are pharmacologically acceptable for administration to human subjects.
The anti-emetic drug is different than the anti-shivering drug, and the anti-emetic drug may comprise one or more substance effective for suppressing nausea and/or vomiting. A variety of such anti-shivering drugs are known or may be identified in the future. Examples of some anti-emetic drugs include certain DZ dopamine antagonists/blocking agents (for example, phenothiazine antipsycotics such as prochlorperazine, triflupromazine, chlorpromazine and trifluoiperazine; and metoclopramide), promethazine (both a D2 dopamine antagonist and an Hl histamine antagonist), certain antihistamines with anticholinergic effects (for example, diphenhydramine, dimenhydrinate and meclizine), and certain serotonin antagonists (for example, ondansetron, granisetron and tropisetron, which are 5-HT3 antagonists).
Preferred for use as the anti-emetic drug is one or more 5-HT3 antagonist.
Also, multiple anti-emetic drugs may be used to the extent they are pharmacologically compatible.
Moreover, as noted above, drugs are often administered in the form of pharmacologically acceptable salts, so for example, the anti-emetic drug may be such a salt of any of the foregoing listed compounds. Ondansetron, or a salt thereof, is particularly preferred for use as the anti-emetic drug.
In one preferred implementation of the invention, the anti-emetic drug comprises a 5-HT3 antagonist and the anti-shivering drug comprises an opioid analgesic. A
particularly preferred pairing is for the anti-emetic drug to comprise ondansetron, or a salt thereof, and the anti-shivering drug to comprise meperidine, or a salt thereof. In one particularly preferred implementation, the use of the anti-emetic drug in combination with the anti-shivering drug reduces the quantity of the anti-shivering drug required to treat for the shivering suppression, relative to use of the anti-shivering drug alone.
For example, an anti-emetic drug can be selected that independently acts to provide at least some level of shivering suppression. This is the case, for example, with the use of ondansetron, , which as noted above has been reported for shivering suppression.
As noted above, each of the anti-emetic drug and the anti-shivering drug should be administered in therapeutically effective quantities. By "effective quantity"
or "therapeutically effective quantity" of the anti-emetic drug and the anti-shivering drug, it is meant that the drug at issue is administered at a dose and with a dosing regimen that is pharmacologically acceptable to treat for the target condition under the circumstances.
As will be appreciated, different people will have varying responses to an "effective quantity".
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
To provide the suppression of shivering while the patient's body temperature is being lowered or while the temperature is in a lowered state, at least a portion of the anti-emetic drug and at least a portion of the anti-shivering drug should be administered prior to commencing the transfer of heat from the body to cool the body and/or while the transfer of heat from the body is being performed during cooling of the body.
The method of administration may be by any suitable administration technique, such as, for example continuous infusion or oral administration. One convenient technique is by intravenous injection as needed.
The anti-emetic drug and the anti-shivering drug may each be administered separately. Each of the anti-emetic drug and the anti-shivering drug may be administered as a single dose, or using a multiple dose regimen involving an initial dose followed by one or more successive, and usually smaller, doses. For the anti-shivering drug, a multiple dose regimen may involve an initial dose to commence the shivering suppression followed by successive doses being administered as required to maintain the shivering suppression. The timing for subsequent dose administrations may be determined, for example by visual observation of the patient for indications that an onset of shivering is approaching. For the anti-emetic drug, a single dose given prior to or soon after commencement of active cooling may be sufficient, although a multiple dose regimen may be better when it is anticipated that cooling and body temperature suppression may extend for a significant duration. For example, an initial dose of the anti-emetic drug may be followed later by one or more supplemental doses as appropriate based on the pharmacokinetic properties'of the specific anti-emetic drug. In one preferred implementation, at least a portion of the anti-emetic drug is administered to the patient prior to commencement of the cooling heat transfer, and also preferably prior to administration of any of the anti-shivering drug.
The active cooling of the patient's body to lower the temperature of the body may be accomplished by transferring heat from the patient's body. This heat transfer may be accomplished using any cooling equipment and techniques, or any combination of such equipment and techniques, including for example, the use of forced air cooling, contact cooling pads and/or the use of endovascular cooling devices and techniques.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
To provide the suppression of shivering while the patient's body temperature is being lowered or while the temperature is in a lowered state, at least a portion of the anti-emetic drug and at least a portion of the anti-shivering drug should be administered prior to commencing the transfer of heat from the body to cool the body and/or while the transfer of heat from the body is being performed during cooling of the body.
The method of administration may be by any suitable administration technique, such as, for example continuous infusion or oral administration. One convenient technique is by intravenous injection as needed.
The anti-emetic drug and the anti-shivering drug may each be administered separately. Each of the anti-emetic drug and the anti-shivering drug may be administered as a single dose, or using a multiple dose regimen involving an initial dose followed by one or more successive, and usually smaller, doses. For the anti-shivering drug, a multiple dose regimen may involve an initial dose to commence the shivering suppression followed by successive doses being administered as required to maintain the shivering suppression. The timing for subsequent dose administrations may be determined, for example by visual observation of the patient for indications that an onset of shivering is approaching. For the anti-emetic drug, a single dose given prior to or soon after commencement of active cooling may be sufficient, although a multiple dose regimen may be better when it is anticipated that cooling and body temperature suppression may extend for a significant duration. For example, an initial dose of the anti-emetic drug may be followed later by one or more supplemental doses as appropriate based on the pharmacokinetic properties'of the specific anti-emetic drug. In one preferred implementation, at least a portion of the anti-emetic drug is administered to the patient prior to commencement of the cooling heat transfer, and also preferably prior to administration of any of the anti-shivering drug.
The active cooling of the patient's body to lower the temperature of the body may be accomplished by transferring heat from the patient's body. This heat transfer may be accomplished using any cooling equipment and techniques, or any combination of such equipment and techniques, including for example, the use of forced air cooling, contact cooling pads and/or the use of endovascular cooling devices and techniques.
In one implementation, the heat transfer may be accomplished with the use of a heat transfer fluid that is at a temperature that is lower than the body temperature of the patient. Air has a low heat capacity, and it is more difficult to achieve quick lowering of the body temperature using air or other gases as a heat transfer fluid, such as with forced air cooling. Liquids generally have higher heat capacities and are preferred for use as a heat transfer fluid.
To effect the heat transfer to cool the patient's body, the heat transfer fluid may be brought into heat transfer communication with the patient's body. With forced air cooling this could be accomplished for example by forcing the air to flow past at least a portion of the body to directly contact the body. A heat transfer liquid could also be directly contacted with a patient's body to effect a transfer of heat from the body, such as for example, by immersing a portion of the patient's body in a reservoir of the liquid.
Heat may also be transferred from the patient's body to a heat transfer fluid without direct contact between the fluid and the body. For example, the fluid may be contained within a heat transfer device that contacts a portion of the body.
For example, when using an catheter device located within the vaculature of the patient, the heat transfer liquid may be forced to flow through the device, with heat being conducted fiom the patient across one or more walls of the device and into the heat transfer fluid, which can be removed from the device to remove the heat from the vicinity of the patient, effecting the desired cooling.
In one preferred implementation, the heat transfer device is contacted with an external dermal surface of the patient. Establishing good heat transfer communication may be aided, for example, by the use of a gel, ointment or other medium between the heat transfer device and the dermal surface. A heat transfer fluid, preferably a liquid, may be circulated through the heat transfer device, wherein heat is conducted from the dermal surface, across one or more wall of the heat transfer device and into the heat transfer fluid.
A contact pad is one preferred heat transfer device for cooling by contact with a dermal surface. Preferably, the contact pad includes an adherent surface to achieve intimate contact with a patient's skin. Such surface may be provided by a thermally-conductive, hydrogel layer juxtaposed to a fluid circulation layer. In the latter regard, the fluid circulation layer may comprise fluid channels and dimples disposed to modify fluid flow characteristics for enhanced heat transfer performance. Examples of contact pads and their operation are disclosed in U.S. Patent No. 6,197,045 entitled "COOLING/I~ATING PAD AND SYSTEM", U.S. Patent No. 6,375,674 entitled "COOLING/I~ATING PAD AND SYSTEM", and U.S. Patent Application Serial No.
10/087,533 having a filing date of February 27, 2002, entitled "IMPROVED
MEDICAL
THERMAL ENERGY EXCHANGE PAD", the entire contents of each of which are incorporated by reference herein as if set forth herein in full. One example of a heat transfer system using one or more contact pads) is described below.
The system includes at least one heat exchanger to effect cooling of a fluid and a circulating pump for circulating the fluid through the heat exchanger and one or more interconnectable contact pad(s). Preferably, circulated fluid is drawn through the contact pads) under negative pressure. Such negative pressure may be established by locating the circulating pump downsheam of the contact pad(s), wherein fluid is effectively pumped out of the contact pads) and then through the heat exchanger and back into the contact pad(s).
One or a plurality of fluid reservoirs may be located downstream of the heat exchanger. For example, a first fluid reservoir may be utilized to contain fluid that is removable therefrom to initially fill and then circulate through the contact pad(s). During normal heat exchange operations, fluid is circulatable through the contact pads) and the heat exchanger by the circulating pump substantially free from passage through the first fluid reservoir. The system may also comprise a second fluid reservoir through which fluid is circulated during normal heat exchange operations. By way of example, the first reservoir may be located to provide direct gravity fluid flow to the second reservoir.
Further, the first reservoir may be vented to facilitate gas removal from the system.
In addition to the noted features, the system may further include various sensors to provide user feedback and automated conhol functionalities, thereby yielding enhanced patient thermal regulation. For example, the system may include a pressure sensor fluidly interconnected between an inlet side of the circulating pump and an outlet port of the interconnectable contact pad(s). Such pressure sensor may provide an output pressure signal employable (e.g. by a processor) to control the circulating pump (e.g.
the flow rate therethrough) and thereby maintain negative pressure within the contact pads) within a predetermined range (e.g. thereby maintaining the desired flow rate through the contact pad(s)). Further, user alerts may be provided when the measured fluid pressure is within a predetermined range.
One or more fluid temperature sensors may also be utilized for sensing the temperature of the circulated fluid and providing an output temperature signals) in response thereto. The output temperature signals) may be utilized (e.g. by a processor) to control the operation of the heat exchanger. For example, the fluid output temperature signals) may be utilized to adjust the fluid temperature to within a predetermined range (e.g. as preset by a user). In this regard, patient temperature may also be monitored, wherein a patient temperature signal and the sensor output temperature signals) may be employed in combination to adjust the circulated fluid temperature. As may be appreciated, such temperature control functionality may be advantageously employed with anti-shivering and anti-emetic drugs in accordance with present invention.
The above-noted system features and additional system functionalities may be incorporated as disclosed in U.S. Patent Application Serial No. 09/976,197, having a filing date of October 11, 2001, entitled "PATIENT TEMPERATURE CONTROL
SYSTEM WTTH FLUID TEMPERATURE RESPONSE", and U.S. Patent Application Serial No. 10/233,843, having a filing date September 3, 2002, entitled "PATIENT
TEMPERATURE CONTROL SYSTEM WITH FLUID TEMPERATURE RESPONSE", the entire contents of each of which are hereby incorporated by reference as if set forth in full hereinbelow.
The degree by which a patient's body temperature is to be lowered will affect the amount of cooling that is used. In some implementations, the patient's body will be lowered by at least 0.5 °C, in other implementations by at least 1°C and by yet other implementations by at least 2 °C. In most situations, the body temperature will be lowered by no more than 5 °C. When reference is made to a person's body temperature, the reference is to the core temperature of the person, not the temperature of extremities.
An indication of the core temperature is determinable, for example by measuring the temperature at a person's tympanic membrane, in a person's rectum or in a person's bladder. The degree by which a person's core temperature is lowered is determinable, for example, by monitoring temperature changes at the tympanic membrane, in the rectum or in the bladder.
EXAMPLES
Mild hypothermia is induced and maintained in healthy subjects for up to several hours. Table 1 summarizes data concerning the subjects for each phase of testing (Phases 1, 3a, 4 and 5). Each volunteer is cooled using contact pads (Arctic Sun Energy Transfer PadsTM, Medivance, Inc., Louisville, Colorado, U.S.A.). Contact pads are applied to _7_ contact the subjects, and water at a controlled temperature is delivered to and circulated through the contact pads to effect the controlled cooling of each volunteer.
TABLE 1. Subject Characteristics Phase Subject # Age (yrs)Sex Weight (kg)Height BSA (M') (cm) 1 1 35 M 66 173 1.79 2 40 M 91 183 2.13 3 41 F 61 165 1.67 4 36 M 91 183 2.13 29 F 68 185 1.90 MeanSD 365 7515 17813 1.92.2 3a 18 21 F 48 163 1.50 19 22 M 98 193 2.29 20 33 F 65 161 1.69 22 25 F 48 164 1.50 23 48 F 67 170 1.78 MeanSD 3011 6520 17013 1.75.3 4 24 26 F 64 152 1.61 25 39 F 74 157 1.75 26 19 M 73 178 1.90 27 2G M 64 165 1.70 MeanSD 288 696 16311 1.74.l 5 29 37 F 51 168 1.57 31 30 M 84 178 2.03 32 35 M 71 178 1.88 33 20 F 61 168 1.69 MeanSD 318 6714 1736 1.79.2 BSA = body surface area Phase 1 Four contact pa ds are applied to the thighs and chest of each subject and each subject is rapidlyd with coole an objective of reducing core body temperature to 34-35 C. Core body temperatures asured at the membrane the rectum.
are me tympanic and Mean skin-surface ghted temperature is average determined from of calf, the wei thigh, chest, and upper vasoconstriction arm skin temperatures. is evaluated Thermoregulatory using forearm minus fingertip skin-temperature gradients. Temperatures are measured using Mon-a-TheimTMthemocouple probes connected to Mallinckrodt Model two-_g_ channel electronic thermometers having an accuracy near 0.1 °C
(Mallinckrodt Anesthesia Products, St. Louis, Missouri, U.S.A.). Temperatures are recorded before cooling is started (i.e., baseline) and subsequently at 15-minute intervals.
Each of subjects 1-5 is administered a single dose of acetomiophen (1000 mg) within 20 minutes prior to treatment and is administered a bolus of intravenous (IV) meperidine (Demerol~, 25-75 mg) within 5 minutes of the start of cooling.
Subjects also receive initial doses of chlorpromazine (Thorazine0, 12.5-25 mg, IV). Active cooling is initiated and the inlet water temperature is controlled to achieve a target tympanic temperature between 34 °C and 35 °C. Additional doses of meperidine and/or chloropromazine are administered to maintain comfort and to prevent shivering.
Active cooling and maintenance of hypothermia continues for up to five hours, after which subjects are actively re-warmed to a tympanic temperature of 36 °C.
The presence of shivering is noted by physical examination, electromyographic artifact on continuous electrocardiography (ECG), or by subject report.
Overall thermal comfort is evaluated at 15-min intervals with a 100-mm-long visual analog scale (VAS) on which 0 mm defines the worst imaginable cold, 50 mm identifies thermal neutrality, and 100 mm indicates unbearable heat. A new, unmarked scale is used for each assessment. Heart rate and oxyhemoglobin saturation are monitored using ECG
and pulse oximetry; arterial blood pressure is recorded oscillometrically at 15-minute intervals.
Phase 3a Five contact pads are applied to the thighs, back and abdomen of each subjects, and actively cooled. Temperatures are measured in the same manner as in Phase 1 except that the rectal temperature probe is connected to a control module and the rectal temperature signal is used by the control module to adjust inlet water temperature via a feedback control algorithm to achieve a target core body temperature of 34.5 °C.
A single oral dose of acetaminophen (1000 mg), is administered within 20 minutes prior to treatment. A bolus of IV meperidine (Demerol0, 50-100mg) is given within 5 minutes of the start of active cooling. Additional doses of meperidine are administered to maintain comfort and to prevent shivering. Active cooling and maintenance of hypothermia continues for five hours. As in the Phase 1, the subjects are actively re-warned to a tympanic temperature of 36 °C prior to termination of the -c~_ experiment. Shivering, comfort, oxyhemoglobin saturation, and arterial blood pressure are recorded as in Phase 1.
Table 2 summarizes results for Phase 1 and Phase 3a. Results are expressed as mean ~SD. Five subjects are enrolled in Phase 1. Subject characteristics are summarized in Table 1. Mild hypothermia is attained in all subjects. The mean time to reach a tympanic temperature of 35 °C is 77~23 minutes which corresponds to a mean cooling rate of 1.5~0.6 °C/hr. Details of the cooling responses of the individual subjects are presented in Table 2. The mean total dosage of meperidine is 280~155mg. Only subjects #1 (37.Smg) and #2 (l2.Smg) received chlorpromazine.
TABLE 2. Cooling Response of Subjects, Phases-1 & 3a Phase Subject T;";tiaiTime to Cooling Total Nausea # or (C) 35C rate Meperidine Vomiting (min) to 35C Dose During (C/hr) (mg) Treatment 1 1 36.8 41 2.6 75 None 2 36.6 82 1.2 200 None 3 36.9 81 1.4 275 Pruritis 4 36.7 105 1.0 375 None 5 37.0 78 1.5 475 None MeanSD 36.8.2 7723 1.5.6 280155 3a 18 37.0 64 1.9 400 Nausea end 19 37.7 180 .9 500 None 36.9 95 1.2 350 Nausea end 22 36.8 56 1.7 350 Nausea early, end 23 36.6 53 1.4 250 Nausea, vomiting mid MeanSD 37Ø4 9053 1.4.4 37091 T = tympanic membrane temperature Six subjects are enrolled in the Phase 3a. One subject is withdrawn from the study 15 prior to the initiation of cooling due to vasovagal syncope at the time of 1V insertion.
Subject characteristics of the remaining 5 subjects are presented in Table 1.
The mean time to reach a tympanic temperature of 35 °C is 90~53 minutes corresponding to a mean cooling rate of 1.4~0.4 °C/hr. Details of the cooling responses of the individual subjects are presented in Table 2. The mean total dosage of meperidine is 370~91 mg.
In all subjects, there is no statistically significant change in heart rate, diastolic blood pressure, or blood oxygenation compared with baseline. Systolic blood pressure is significantly elevated compared with baseline only for the 180min timepoint (140~20 vs 122~13 mm Hg; p=.042). The mean total meperidine dosage in Phase 3a is 90mg higher than in Phase 1 (370mg vs 280mg; p= 0.28, t-test). Comfort is statistically significantly lower than baseline for all timepoints during active cooling (except T=135min) although no subject requested that the study be terminated.
In Phases 1 and 3a, meperidine is used to suppress shivering and to maintain comfort. Although no respiratory compromise is observed, nausea is observed in 30% of subjects. All cases of nausea occurred in Phase 3a making the trend toward a higher total meperidine dosage in Phase 3a noteworthy.
Phase 4 Phase 4 proceeds as described for Phase 3a, except as noted. In addition to meperidine (Demerol0), subjects are also given an oral dose of 30-60mg buspirone.
Subject characteristics are summarized in Table 1. Results are summarized in Table 3.
Five subjects are enrolled in Phase 4. One subject is withdrawn due to sustained nausea and vomiting throughout the treatment period. Details of the cooling responses of the individual subjects are presented in Table 3. As seen in Table 3, the use of buspirone did not reduce the incidence of nausea in those four subjects.
TABLE 3. Cooling Response of Subjects, Phase 4 Phase Subject # T;";c,ai Time to Cooling Total Nausea or (°C) 35°C (min) rate Meperidine Vomiting to 35°C Dose During (°C/hr) (mg) Treatment 4 24 36.9 63 1.9 250 Nausea mid 37.3 158 0.8 400 Nausea end 26 37.0 105 1.1 250 Nausea early, Vomiting end 27 36.8 95 1.1 250 None MeanSD 37Ø2 10539 1.2.5 28875 25 T = tympanic membrane temperature Phase 5 Phase 5 proceeds as described for Phase 3a, except as noted. The temperature of water circulated to the contact pads is controlled to achieve a target core body temperature of 34.5 °C. In addition to meperidine (Demerol0), subjects are also given an IV dose of 8 mg ondansetron (hydrochloride salt, Glaxo Wellcome). Subject characteristics are summarized in Table 1. Results are summarized in Table 4.
Five subjects are enrolled in Phase 5. One subject is withdrawn due to a mild allergic reaction to meperidine, which caused a facial rash. Mild hypothermia is attained in all subjects. the mean time to reach a tympanic temperature of 35.0 °C is 72~15 minutes, coiTesponding to a cooling rate of 1.6 °C/hr. Details of the cooling responses of the individual subjects are presented in Table 4. The mean total dosage of rneperidine is 306~55 mg.
Subject #29 feels very warm at the end of the treatment, and becomes nauseated and vomits immediately after the treatment. The nausea and vomiting is believed to be due to a fast rate of warming of the subject. The rate of warming is reduced for subsequent subjects, who do not become nauseated and do not vomit during the treatment. Thus, the use of ondansehon reduces the incidence of nausea and vomiting, relative to Phases 3a and 4. In addition, there is a trend toward less meperidine administration in Phase 5 relative to Phase 3a (p=0.26, t-test). Furthermore, the mean comfort score for the subjects is higher in Phase 5 than in Phases 1, 3a and 4.
TABLE 4. Cooling Response of Subjects, Phase 5 Phase Subject # T;"itiai Time to CoolingTotal Nausea or (C) 35C rate MeperidineVomiting (min) to 35C Dose During (C/hr) (mg) Treatment 5 29 36.9 60 1.9 375 Nausea and vomiting immediately post 31 37.0 80 1.5 275 None 32 36.4 58 1.4 250 None 33 37.3 88 1.6 325 Nausea post Mean~SD 36.9~.4 72~15 1.6~.2 306~55 T = tympanic membrane temperature Moreover, during a subsequent test conducted in a manner similar to that described for Phase 5, a subject was administered an initial dose of 8 mg of the ondansetron followed by a supplemental dose of 8 mg of the ondansetron administered 3.5 hours later. The subject did not experience nausea.
The foregoing discussion of the invention has been presented for proposes of illustration and description. The foregoing is not intended to limit the invention to only the foam or forms specifically disclosed herein. Although the description of the invention has included description of one or more possible implementations and certain variations and modifications, other variations and modifications are within the scope of the invention, e.g., as may be within the skill and knowledge of those in the art after understanding the present disclosure. It is intended to obtain, rights which include alternative embodiments to the extent permitted, including alternate, interchangeable andlor equivalent structures, functions, ranges or steps to those claimed, whether or not such alternate, interchangeable and/or equivalent structures, functions, ranges or steps are disclosed herein, and without intending to publicly dedicate any patentable subject matter.
Furthermore, any feature described with respect to any disclosed implementation may be combined in any combination with one or more features of any other implementation or implementations. Moreover, the invention specifically includes use of the anti-shivering drug and the anti-emetic drug in any implementation disclosed herein, the manufacture of the anti-emetic drug and/or the anti-shivering drug for use to manufacture a medicament for use in any of the disclosed herein, and any other use, manipulation or processing of the anti-emetic drug and/or the anti-shivering drug in preparation for use in any implementation disclosed herein.
The terms "comprise", "include", "have" and "contain", and variations of those terms, as may be used in relation to the presence any feature described or claimed, are intended to indicate only that a particular feature is present to an extent as specified, and are not intended to limit the presence of that feature beyond the extent specified or the presence of other features.
To effect the heat transfer to cool the patient's body, the heat transfer fluid may be brought into heat transfer communication with the patient's body. With forced air cooling this could be accomplished for example by forcing the air to flow past at least a portion of the body to directly contact the body. A heat transfer liquid could also be directly contacted with a patient's body to effect a transfer of heat from the body, such as for example, by immersing a portion of the patient's body in a reservoir of the liquid.
Heat may also be transferred from the patient's body to a heat transfer fluid without direct contact between the fluid and the body. For example, the fluid may be contained within a heat transfer device that contacts a portion of the body.
For example, when using an catheter device located within the vaculature of the patient, the heat transfer liquid may be forced to flow through the device, with heat being conducted fiom the patient across one or more walls of the device and into the heat transfer fluid, which can be removed from the device to remove the heat from the vicinity of the patient, effecting the desired cooling.
In one preferred implementation, the heat transfer device is contacted with an external dermal surface of the patient. Establishing good heat transfer communication may be aided, for example, by the use of a gel, ointment or other medium between the heat transfer device and the dermal surface. A heat transfer fluid, preferably a liquid, may be circulated through the heat transfer device, wherein heat is conducted from the dermal surface, across one or more wall of the heat transfer device and into the heat transfer fluid.
A contact pad is one preferred heat transfer device for cooling by contact with a dermal surface. Preferably, the contact pad includes an adherent surface to achieve intimate contact with a patient's skin. Such surface may be provided by a thermally-conductive, hydrogel layer juxtaposed to a fluid circulation layer. In the latter regard, the fluid circulation layer may comprise fluid channels and dimples disposed to modify fluid flow characteristics for enhanced heat transfer performance. Examples of contact pads and their operation are disclosed in U.S. Patent No. 6,197,045 entitled "COOLING/I~ATING PAD AND SYSTEM", U.S. Patent No. 6,375,674 entitled "COOLING/I~ATING PAD AND SYSTEM", and U.S. Patent Application Serial No.
10/087,533 having a filing date of February 27, 2002, entitled "IMPROVED
MEDICAL
THERMAL ENERGY EXCHANGE PAD", the entire contents of each of which are incorporated by reference herein as if set forth herein in full. One example of a heat transfer system using one or more contact pads) is described below.
The system includes at least one heat exchanger to effect cooling of a fluid and a circulating pump for circulating the fluid through the heat exchanger and one or more interconnectable contact pad(s). Preferably, circulated fluid is drawn through the contact pads) under negative pressure. Such negative pressure may be established by locating the circulating pump downsheam of the contact pad(s), wherein fluid is effectively pumped out of the contact pads) and then through the heat exchanger and back into the contact pad(s).
One or a plurality of fluid reservoirs may be located downstream of the heat exchanger. For example, a first fluid reservoir may be utilized to contain fluid that is removable therefrom to initially fill and then circulate through the contact pad(s). During normal heat exchange operations, fluid is circulatable through the contact pads) and the heat exchanger by the circulating pump substantially free from passage through the first fluid reservoir. The system may also comprise a second fluid reservoir through which fluid is circulated during normal heat exchange operations. By way of example, the first reservoir may be located to provide direct gravity fluid flow to the second reservoir.
Further, the first reservoir may be vented to facilitate gas removal from the system.
In addition to the noted features, the system may further include various sensors to provide user feedback and automated conhol functionalities, thereby yielding enhanced patient thermal regulation. For example, the system may include a pressure sensor fluidly interconnected between an inlet side of the circulating pump and an outlet port of the interconnectable contact pad(s). Such pressure sensor may provide an output pressure signal employable (e.g. by a processor) to control the circulating pump (e.g.
the flow rate therethrough) and thereby maintain negative pressure within the contact pads) within a predetermined range (e.g. thereby maintaining the desired flow rate through the contact pad(s)). Further, user alerts may be provided when the measured fluid pressure is within a predetermined range.
One or more fluid temperature sensors may also be utilized for sensing the temperature of the circulated fluid and providing an output temperature signals) in response thereto. The output temperature signals) may be utilized (e.g. by a processor) to control the operation of the heat exchanger. For example, the fluid output temperature signals) may be utilized to adjust the fluid temperature to within a predetermined range (e.g. as preset by a user). In this regard, patient temperature may also be monitored, wherein a patient temperature signal and the sensor output temperature signals) may be employed in combination to adjust the circulated fluid temperature. As may be appreciated, such temperature control functionality may be advantageously employed with anti-shivering and anti-emetic drugs in accordance with present invention.
The above-noted system features and additional system functionalities may be incorporated as disclosed in U.S. Patent Application Serial No. 09/976,197, having a filing date of October 11, 2001, entitled "PATIENT TEMPERATURE CONTROL
SYSTEM WTTH FLUID TEMPERATURE RESPONSE", and U.S. Patent Application Serial No. 10/233,843, having a filing date September 3, 2002, entitled "PATIENT
TEMPERATURE CONTROL SYSTEM WITH FLUID TEMPERATURE RESPONSE", the entire contents of each of which are hereby incorporated by reference as if set forth in full hereinbelow.
The degree by which a patient's body temperature is to be lowered will affect the amount of cooling that is used. In some implementations, the patient's body will be lowered by at least 0.5 °C, in other implementations by at least 1°C and by yet other implementations by at least 2 °C. In most situations, the body temperature will be lowered by no more than 5 °C. When reference is made to a person's body temperature, the reference is to the core temperature of the person, not the temperature of extremities.
An indication of the core temperature is determinable, for example by measuring the temperature at a person's tympanic membrane, in a person's rectum or in a person's bladder. The degree by which a person's core temperature is lowered is determinable, for example, by monitoring temperature changes at the tympanic membrane, in the rectum or in the bladder.
EXAMPLES
Mild hypothermia is induced and maintained in healthy subjects for up to several hours. Table 1 summarizes data concerning the subjects for each phase of testing (Phases 1, 3a, 4 and 5). Each volunteer is cooled using contact pads (Arctic Sun Energy Transfer PadsTM, Medivance, Inc., Louisville, Colorado, U.S.A.). Contact pads are applied to _7_ contact the subjects, and water at a controlled temperature is delivered to and circulated through the contact pads to effect the controlled cooling of each volunteer.
TABLE 1. Subject Characteristics Phase Subject # Age (yrs)Sex Weight (kg)Height BSA (M') (cm) 1 1 35 M 66 173 1.79 2 40 M 91 183 2.13 3 41 F 61 165 1.67 4 36 M 91 183 2.13 29 F 68 185 1.90 MeanSD 365 7515 17813 1.92.2 3a 18 21 F 48 163 1.50 19 22 M 98 193 2.29 20 33 F 65 161 1.69 22 25 F 48 164 1.50 23 48 F 67 170 1.78 MeanSD 3011 6520 17013 1.75.3 4 24 26 F 64 152 1.61 25 39 F 74 157 1.75 26 19 M 73 178 1.90 27 2G M 64 165 1.70 MeanSD 288 696 16311 1.74.l 5 29 37 F 51 168 1.57 31 30 M 84 178 2.03 32 35 M 71 178 1.88 33 20 F 61 168 1.69 MeanSD 318 6714 1736 1.79.2 BSA = body surface area Phase 1 Four contact pa ds are applied to the thighs and chest of each subject and each subject is rapidlyd with coole an objective of reducing core body temperature to 34-35 C. Core body temperatures asured at the membrane the rectum.
are me tympanic and Mean skin-surface ghted temperature is average determined from of calf, the wei thigh, chest, and upper vasoconstriction arm skin temperatures. is evaluated Thermoregulatory using forearm minus fingertip skin-temperature gradients. Temperatures are measured using Mon-a-TheimTMthemocouple probes connected to Mallinckrodt Model two-_g_ channel electronic thermometers having an accuracy near 0.1 °C
(Mallinckrodt Anesthesia Products, St. Louis, Missouri, U.S.A.). Temperatures are recorded before cooling is started (i.e., baseline) and subsequently at 15-minute intervals.
Each of subjects 1-5 is administered a single dose of acetomiophen (1000 mg) within 20 minutes prior to treatment and is administered a bolus of intravenous (IV) meperidine (Demerol~, 25-75 mg) within 5 minutes of the start of cooling.
Subjects also receive initial doses of chlorpromazine (Thorazine0, 12.5-25 mg, IV). Active cooling is initiated and the inlet water temperature is controlled to achieve a target tympanic temperature between 34 °C and 35 °C. Additional doses of meperidine and/or chloropromazine are administered to maintain comfort and to prevent shivering.
Active cooling and maintenance of hypothermia continues for up to five hours, after which subjects are actively re-warmed to a tympanic temperature of 36 °C.
The presence of shivering is noted by physical examination, electromyographic artifact on continuous electrocardiography (ECG), or by subject report.
Overall thermal comfort is evaluated at 15-min intervals with a 100-mm-long visual analog scale (VAS) on which 0 mm defines the worst imaginable cold, 50 mm identifies thermal neutrality, and 100 mm indicates unbearable heat. A new, unmarked scale is used for each assessment. Heart rate and oxyhemoglobin saturation are monitored using ECG
and pulse oximetry; arterial blood pressure is recorded oscillometrically at 15-minute intervals.
Phase 3a Five contact pads are applied to the thighs, back and abdomen of each subjects, and actively cooled. Temperatures are measured in the same manner as in Phase 1 except that the rectal temperature probe is connected to a control module and the rectal temperature signal is used by the control module to adjust inlet water temperature via a feedback control algorithm to achieve a target core body temperature of 34.5 °C.
A single oral dose of acetaminophen (1000 mg), is administered within 20 minutes prior to treatment. A bolus of IV meperidine (Demerol0, 50-100mg) is given within 5 minutes of the start of active cooling. Additional doses of meperidine are administered to maintain comfort and to prevent shivering. Active cooling and maintenance of hypothermia continues for five hours. As in the Phase 1, the subjects are actively re-warned to a tympanic temperature of 36 °C prior to termination of the -c~_ experiment. Shivering, comfort, oxyhemoglobin saturation, and arterial blood pressure are recorded as in Phase 1.
Table 2 summarizes results for Phase 1 and Phase 3a. Results are expressed as mean ~SD. Five subjects are enrolled in Phase 1. Subject characteristics are summarized in Table 1. Mild hypothermia is attained in all subjects. The mean time to reach a tympanic temperature of 35 °C is 77~23 minutes which corresponds to a mean cooling rate of 1.5~0.6 °C/hr. Details of the cooling responses of the individual subjects are presented in Table 2. The mean total dosage of meperidine is 280~155mg. Only subjects #1 (37.Smg) and #2 (l2.Smg) received chlorpromazine.
TABLE 2. Cooling Response of Subjects, Phases-1 & 3a Phase Subject T;";tiaiTime to Cooling Total Nausea # or (C) 35C rate Meperidine Vomiting (min) to 35C Dose During (C/hr) (mg) Treatment 1 1 36.8 41 2.6 75 None 2 36.6 82 1.2 200 None 3 36.9 81 1.4 275 Pruritis 4 36.7 105 1.0 375 None 5 37.0 78 1.5 475 None MeanSD 36.8.2 7723 1.5.6 280155 3a 18 37.0 64 1.9 400 Nausea end 19 37.7 180 .9 500 None 36.9 95 1.2 350 Nausea end 22 36.8 56 1.7 350 Nausea early, end 23 36.6 53 1.4 250 Nausea, vomiting mid MeanSD 37Ø4 9053 1.4.4 37091 T = tympanic membrane temperature Six subjects are enrolled in the Phase 3a. One subject is withdrawn from the study 15 prior to the initiation of cooling due to vasovagal syncope at the time of 1V insertion.
Subject characteristics of the remaining 5 subjects are presented in Table 1.
The mean time to reach a tympanic temperature of 35 °C is 90~53 minutes corresponding to a mean cooling rate of 1.4~0.4 °C/hr. Details of the cooling responses of the individual subjects are presented in Table 2. The mean total dosage of meperidine is 370~91 mg.
In all subjects, there is no statistically significant change in heart rate, diastolic blood pressure, or blood oxygenation compared with baseline. Systolic blood pressure is significantly elevated compared with baseline only for the 180min timepoint (140~20 vs 122~13 mm Hg; p=.042). The mean total meperidine dosage in Phase 3a is 90mg higher than in Phase 1 (370mg vs 280mg; p= 0.28, t-test). Comfort is statistically significantly lower than baseline for all timepoints during active cooling (except T=135min) although no subject requested that the study be terminated.
In Phases 1 and 3a, meperidine is used to suppress shivering and to maintain comfort. Although no respiratory compromise is observed, nausea is observed in 30% of subjects. All cases of nausea occurred in Phase 3a making the trend toward a higher total meperidine dosage in Phase 3a noteworthy.
Phase 4 Phase 4 proceeds as described for Phase 3a, except as noted. In addition to meperidine (Demerol0), subjects are also given an oral dose of 30-60mg buspirone.
Subject characteristics are summarized in Table 1. Results are summarized in Table 3.
Five subjects are enrolled in Phase 4. One subject is withdrawn due to sustained nausea and vomiting throughout the treatment period. Details of the cooling responses of the individual subjects are presented in Table 3. As seen in Table 3, the use of buspirone did not reduce the incidence of nausea in those four subjects.
TABLE 3. Cooling Response of Subjects, Phase 4 Phase Subject # T;";c,ai Time to Cooling Total Nausea or (°C) 35°C (min) rate Meperidine Vomiting to 35°C Dose During (°C/hr) (mg) Treatment 4 24 36.9 63 1.9 250 Nausea mid 37.3 158 0.8 400 Nausea end 26 37.0 105 1.1 250 Nausea early, Vomiting end 27 36.8 95 1.1 250 None MeanSD 37Ø2 10539 1.2.5 28875 25 T = tympanic membrane temperature Phase 5 Phase 5 proceeds as described for Phase 3a, except as noted. The temperature of water circulated to the contact pads is controlled to achieve a target core body temperature of 34.5 °C. In addition to meperidine (Demerol0), subjects are also given an IV dose of 8 mg ondansetron (hydrochloride salt, Glaxo Wellcome). Subject characteristics are summarized in Table 1. Results are summarized in Table 4.
Five subjects are enrolled in Phase 5. One subject is withdrawn due to a mild allergic reaction to meperidine, which caused a facial rash. Mild hypothermia is attained in all subjects. the mean time to reach a tympanic temperature of 35.0 °C is 72~15 minutes, coiTesponding to a cooling rate of 1.6 °C/hr. Details of the cooling responses of the individual subjects are presented in Table 4. The mean total dosage of rneperidine is 306~55 mg.
Subject #29 feels very warm at the end of the treatment, and becomes nauseated and vomits immediately after the treatment. The nausea and vomiting is believed to be due to a fast rate of warming of the subject. The rate of warming is reduced for subsequent subjects, who do not become nauseated and do not vomit during the treatment. Thus, the use of ondansehon reduces the incidence of nausea and vomiting, relative to Phases 3a and 4. In addition, there is a trend toward less meperidine administration in Phase 5 relative to Phase 3a (p=0.26, t-test). Furthermore, the mean comfort score for the subjects is higher in Phase 5 than in Phases 1, 3a and 4.
TABLE 4. Cooling Response of Subjects, Phase 5 Phase Subject # T;"itiai Time to CoolingTotal Nausea or (C) 35C rate MeperidineVomiting (min) to 35C Dose During (C/hr) (mg) Treatment 5 29 36.9 60 1.9 375 Nausea and vomiting immediately post 31 37.0 80 1.5 275 None 32 36.4 58 1.4 250 None 33 37.3 88 1.6 325 Nausea post Mean~SD 36.9~.4 72~15 1.6~.2 306~55 T = tympanic membrane temperature Moreover, during a subsequent test conducted in a manner similar to that described for Phase 5, a subject was administered an initial dose of 8 mg of the ondansetron followed by a supplemental dose of 8 mg of the ondansetron administered 3.5 hours later. The subject did not experience nausea.
The foregoing discussion of the invention has been presented for proposes of illustration and description. The foregoing is not intended to limit the invention to only the foam or forms specifically disclosed herein. Although the description of the invention has included description of one or more possible implementations and certain variations and modifications, other variations and modifications are within the scope of the invention, e.g., as may be within the skill and knowledge of those in the art after understanding the present disclosure. It is intended to obtain, rights which include alternative embodiments to the extent permitted, including alternate, interchangeable andlor equivalent structures, functions, ranges or steps to those claimed, whether or not such alternate, interchangeable and/or equivalent structures, functions, ranges or steps are disclosed herein, and without intending to publicly dedicate any patentable subject matter.
Furthermore, any feature described with respect to any disclosed implementation may be combined in any combination with one or more features of any other implementation or implementations. Moreover, the invention specifically includes use of the anti-shivering drug and the anti-emetic drug in any implementation disclosed herein, the manufacture of the anti-emetic drug and/or the anti-shivering drug for use to manufacture a medicament for use in any of the disclosed herein, and any other use, manipulation or processing of the anti-emetic drug and/or the anti-shivering drug in preparation for use in any implementation disclosed herein.
The terms "comprise", "include", "have" and "contain", and variations of those terms, as may be used in relation to the presence any feature described or claimed, are intended to indicate only that a particular feature is present to an extent as specified, and are not intended to limit the presence of that feature beyond the extent specified or the presence of other features.
Claims (64)
1. A method for lowering the body temperature of a human, the method comprising:
transferring heat from the body of the human;
administering to the human an anti-emetic drug in an effective quantity for treatment to suppress nausea during the transferring; and administering to the human an anti-shivering drug in effective quantity for treatment to suppress shivering during the transferring.
transferring heat from the body of the human;
administering to the human an anti-emetic drug in an effective quantity for treatment to suppress nausea during the transferring; and administering to the human an anti-shivering drug in effective quantity for treatment to suppress shivering during the transferring.
2. The method of Claim 1, wherein during the administering the anti-emetic drug, a dose of the anti-emetic drug is administered to the human prior to commencement of the transferring.
3. The method of Claim 1, wherein during the administering the anti-emetic drug, a dose of the anti-emetic drug is administered to the human prior to commencement of the administering of the anti-shivering drug.
4. The method of Claim 1, wherein the administering the anti-shivering drug comprises a multi-dose administration regimen;
the multiple-dose administration regimen comprising a first dose of the anti-shivering drug administered to the human prior to commencement of or during the transferring;
the multiple-dose administration regiment comprising a second dose of the anti-shivering drug administered to the human during the transferring and after administration of the first dose.
the multiple-dose administration regimen comprising a first dose of the anti-shivering drug administered to the human prior to commencement of or during the transferring;
the multiple-dose administration regiment comprising a second dose of the anti-shivering drug administered to the human during the transferring and after administration of the first dose.
5. The method of Claim 4, wherein the administering the anti-emetic drug comprises administering a dose of the anti-emetic drug prior to the first dose of the anti-shivering drug.
6. The method of Claim 1, wherein the anti-shivering drug comprises an analgesic.
7. The method of Claim 1, wherein the anti-shivering drug comprises an opioid analgesic.
8. The method of Claim 7, wherein the opioid analgesic is selected from the group consisting of alfentanil, morphine, fentanyl, meperidine, naloxone, nalbuphine and combinations of any of the foregoing.
9. The method of Claim 1, wherein the anti-shivering drug comprises meperidine.
10. The method of Claim 1, wherein the anti-emetic drug comprises a serotonin antagonist.
11. The method of Claim 10, wherein the anti-emetic drug comprises a 5-HT3 antagonist.
12. The method of Claim 11, wherein the anti-emetic drug is selected from the group consisting of ondansetron, granisetron, tropisetron and combinations of any of the foregoing.
13. The method of Claim 1, wherein the anti-emetic drug comprises ondansetron.
14. The method of Claim 1, wherein the anti-shivering drug comprises meperidine and the anti-emetic drug comprises ondansetron.
15. The method of Claim 1, wherein the transferring comprises transfer of heat from the body of the human into a heat transfer fluid brought into heat transfer communication with the human body.
16. The method of Claim 15, wherein the transferring comprises flowing the heat transfer fluid through a heat transfer device in heat transfer communication with an exterior dermal surface, whereby heat is hansferred from the human across the dermal surface and into the heat transfer fluid flowing through the heat transfer device.
17. The method of Claim 16, wherein the heat transfer device comprises a contact cooling pad and the heat transfer fluid is a liquid.
18. The method of Claim 17, wherein the liquid comprises water.
19. The method of Claim 17, wherein the contact cooling pad comprises an adherent surface in contact with the dermal surface during the transferring.
20. The method of Claim 19, wherein the adherent surface comprises a thermally conductive hydrogel layer.
21. The method of Claim 15, wherein during the transferring, the heat transfer fluid is introduced into a heat transfer device located within the vasculature of the human.
22. The method of Claim 1, wherein the transferring comprises reducing the core temperature of the human by at least 1°C.
23. The method of Claim 1, wherein the transferring comprises reducing the core temperature of the human in a range of from 1°C to 5°C.
24. The method of Claim 1, wherein the anti-emetic drug reduces the quantity of the anti-shivering drug required during the administering the anti-shivering drug for the treatment to suppress shivering during the transferring.
25. The method of Claim 1, wherein during the transferring comprises inducing hypothermia in the human.
26. The method of Claim 25, wherein the human is suffering a condition involving reduced blood supply.
27. The method of Claim 26, wherein the condition comprises at least one of stroke, myocardial infarction and cardiac arrest.
28. A method for lowering the body temperature of a human, the method comprising:
transferring heat from the body of the human;
administering to the human prior to or during the transferring an opioid analgesic;
and administering to the human prior to or during the transferring a 5-HT3 antagonist;
the opioid analgesic and the 5-HT3 antagonist being administered in effective quantities for treatment to manage shivering and nausea during the transferring.
transferring heat from the body of the human;
administering to the human prior to or during the transferring an opioid analgesic;
and administering to the human prior to or during the transferring a 5-HT3 antagonist;
the opioid analgesic and the 5-HT3 antagonist being administered in effective quantities for treatment to manage shivering and nausea during the transferring.
29. The method of Claim 28, wherein the transferring heat from the body of the human comprises lowering the core temperature of the human by at least 0.5 °C.
30. The method of Claim 29, wherein the transferring heat from the body of the human to a heat exchange fluid contained within a heat exchange device in heat transfer communication with the body of the human.
31. The method of Claim 30, wherein during the transferring heat from the body of the human, the heat exchange device is in heat transfer communication with a dermal surface of the human and heat is transferred across the dermal surface and to the heat exchange fluid.
32. The method of Claim 31, wherein the heat exchange device comprises a contact cooling pad and the heat exchange fluid is a liquid flowing through the contact cooling pad.
33. The method of Claim 30, wherein the administering the anti-emetic drug comprises administering a dose of the anti-emetic drug to the human prior to commencement of the transferring heat from the body of the human.
34. The method of Claim 33, wherein the administering the anti-shivering drug comprises a multiple dose administration regimen comprising at least two separate doses of the anti-shivering drug administered to the human after the administering the dose of the anti-emetic drug to the human.
35. The method of Claim 33, wherein the 5-HT3 antagonist comprises ondansetron.
36. The method of Claim 35, wherein the opioid analgesic comprises meperidine.
37. A method for suppressing shivering during active cooling of a human body, comprising administering a 5-HT3 antagonist to the human prior to or during the active cooling.
38. The method of Claim 37, wherein the active cooling comprises inducing hypothermia.
39. Use of a combination of an anti-shivering drug and an anti-emetic drug for treatment to suppress shivering during active cooling of a human to reduce the body temperature of the human.
40. The use of Claim 39, wherein the anti-shivering drug comprises an analgesic.
41. The use of either one of Claims 39 and 40, wherein the anti-shivering drug comprises an opioid analgesic.
42. The use of any one of Claims 39 through 41, wherein the opioid analgesic is selected from the group consisting of alfentanil, morphine, fentanyl, meperidine, naloxone, nalbuphine and combinations of any of the foregoing.
43. The use of any one of Claims 39 through 42, wherein the anti-shivering drug comprises meperidine.
44. The use of any one of Claims 39 through 43, wherein the anti-emetic drug comprises a serotonin antagonist.
45. The use of any one of Claims 39 through 43, wherein the anti-emetic drug comprises a 5-HT3 antagonist.
46. The use of any one of Claims 39 through 43, wherein the anti-emetic drug is selected from the group consisting of ondansetron, granisetron, tropisetron and combinations of any of the foregoing.
47. The use of any one of Claims 39 through 43, wherein the anti-emetic drug comprises ondansetron.
48. The use of any one of Claim 39, wherein the anti-shivering drug comprises meperidine and the anti-emetic drug comprises ondansetron.
49. The use of any one of Claims 39 through 48, wherein the active cooling comprises transferring heat from the body of the human into a heat transfer fluid brought into heat transfer communication with the human body.
50. The use of Claim 49, wherein the transferring comprises flowing the heat transfer fluid through a heat transfer device in heat transfer communication with an exterior dermal surface of the human, whereby heat is transferred from the human across the dermal surface and into the heat transfer fluid flowing through the heat transfer device.
51. The use of Claim 50, wherein the heat transfer device comprises a contact cooling pad and the heat transfer fluid is a liquid.
52. The use of any one of Claims 39 through 51, wherein during the active cooling, hypothermia is induced in the human.
53. The use of any one of Claims 39 through 52, wherein the human is suffering a condition involving reduced blood supply.
54. The use of Claim 53, wherein the condition comprises at least one of stroke, myocardial infarction and cardiac arrest.
55. The use of any one of Claims 39 through 54, wherein during the active cooling, a core temperature of the human is reduced by at least 1°C.
56. The use of any one of Claims 39 through 54, wherein during the active cooling, the core temperature of the human is reduced by an amount within a range of from 1 °C to 5 °C.
57. Use of an anti-emetic substance for preparation of a medicament for treatment in combination with an anti-shivering drug for suppression of shivering during active cooling of a human to reduce the body temperature of the human.
58. Use of an anti-shivering substance for preparation of a medicament for treatment in combination with an anti-emetic drug for suppression of shivering during active cooling of a human to reduce the body temperature of the human.
59. Use of a 5-HT3 antagonist for preparation of a medicament for treatment to suppress shivering during active cooling of a human to reduce the body temperature of the human.
60. Use of an anti-emetic substance for preparation of a medicament for treatment of a human, in combination with an anti-shivering drug, for reduced blood supply.
61. Use of an anti-shivering substance for preparation of a medicament for treatment of a human, in combination with an anti-emetic drug, for reduced blood supply.
62. Use of a 5-HT3 antagonist for preparation of a medicament for treatment of a human for reduced blood supply.
63. The use of any one of Claims 60 through 62, wherein the reduced blood supply is associated with one or more of stroke, myocardial infarction and cardiac arrest
64. The use of any one of Claims 60 through 63, wherein the treatment comprises active cooling of the human to reduce the body temperature of the human and induce hypothemia.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42310602P | 2002-11-01 | 2002-11-01 | |
| US60/423,106 | 2002-11-01 | ||
| US10/405,301 | 2003-04-02 | ||
| US10/405,301 US20040087606A1 (en) | 2002-11-01 | 2003-04-02 | Shivering suppression during cooling to lower body temperature |
| PCT/US2003/034317 WO2004041171A2 (en) | 2002-11-01 | 2003-10-30 | Shivering supression during cooling to lower body temperature |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2517456A1 true CA2517456A1 (en) | 2004-05-21 |
Family
ID=32179684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002517456A Abandoned CA2517456A1 (en) | 2002-11-01 | 2003-10-30 | Shivering suppression during cooling to lower body temperature |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040087606A1 (en) |
| EP (1) | EP1567153A4 (en) |
| JP (1) | JP2006504805A (en) |
| AU (1) | AU2003288954A1 (en) |
| CA (1) | CA2517456A1 (en) |
| WO (1) | WO2004041171A2 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7458984B2 (en) * | 1998-01-23 | 2008-12-02 | Innercool Therapies, Inc. | System and method for inducing hypothermia with active patient temperature control employing catheter-mounted temperature sensor and temperature projection algorithm |
| US6464716B1 (en) | 1998-01-23 | 2002-10-15 | Innercool Therapies, Inc. | Selective organ cooling apparatus and method |
| US7547320B2 (en) * | 2002-07-11 | 2009-06-16 | Life Recovery System Hd, Llc | Apparatus for altering the body temperature of a patient |
| US7666213B2 (en) * | 2002-07-11 | 2010-02-23 | Life Recovery Systems Hd, Llc | Apparatus for altering the body temperature of a patient |
| CA2411569A1 (en) * | 2002-11-12 | 2004-05-12 | Ross E. Mantle | Medical device for the extravascular recirculation of fluid in body cavities at controlled temperature and pressure |
| US7361186B2 (en) * | 2003-08-25 | 2008-04-22 | Medivance, Incorporated | Active body cooling with vasodilation to reduce body temperature |
| US7377935B2 (en) | 2004-09-24 | 2008-05-27 | Life Recovery Systems Hd, Llc | Apparatus for altering the body temperature of a patient |
| US20180311071A1 (en) | 2005-10-21 | 2018-11-01 | Daniel R. BURNETT | Method and apparatus for peritoneal oxygenation |
| US20070093697A1 (en) * | 2005-10-21 | 2007-04-26 | Theranova, Llc | Method and apparatus for detection of right to left shunting in the cardiopulmonary vasculature |
| US7771461B2 (en) | 2006-08-24 | 2010-08-10 | Life Recovery Systems Hd, Llc | Apparatus for altering the body temperature of a patient |
| EP2155300A1 (en) | 2007-04-05 | 2010-02-24 | Velomedix, Inc | Automated therapy system and method |
| CA2693774A1 (en) * | 2007-07-09 | 2009-01-15 | Velomedix, Inc. | Hypothermia devices and methods |
| US8475509B2 (en) * | 2007-08-09 | 2013-07-02 | Zoll Circulation, Inc. | Devices and methods for using endovascular cooling to treat septic shock and other disorders |
| EP3677228A1 (en) | 2007-10-12 | 2020-07-08 | Medivance Incorporated | Improved system for patient temperature control |
| WO2009065138A1 (en) * | 2007-11-16 | 2009-05-22 | Medivance Incorporated | Patient temperature response control system and method |
| JP5676455B2 (en) * | 2008-10-08 | 2015-02-25 | ベッドロック・インヴェンションズ・エルエルシー | Apparatus for measuring and processing shivering (vibration) during temperature control for treatment and temperature management system for treatment |
| AU2009313320A1 (en) * | 2008-11-07 | 2010-05-14 | Velomedix, Inc. | Devices and methods for monitoring core temperature and an intraperitoneal parameter |
| WO2011074695A1 (en) * | 2009-12-18 | 2011-06-23 | Suzuki Manzo | Shivering suppressor |
| WO2012006625A2 (en) | 2010-07-09 | 2012-01-12 | Velomedix, Inc. | Method and apparatus for pressure measurement |
| CN106573101B (en) | 2014-08-14 | 2020-02-11 | 梅迪万斯股份有限公司 | System and method for extracorporeal blood temperature control |
| JP6787903B2 (en) | 2015-01-27 | 2020-11-18 | メディヴァンス インコーポレイテッドＭｅｄｉｖａｎｃｅ，Ｉｎｃ． | Improved medical pads and systems for hyperthermia |
| EP3355960A1 (en) * | 2015-09-30 | 2018-08-08 | Seiratherm GmbH | Shivering adjustment infusion system and method |
| US10993829B2 (en) | 2016-11-23 | 2021-05-04 | Stryker Corporation | Thermal system |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6843800B1 (en) * | 1998-01-23 | 2005-01-18 | Innercool Therapies, Inc. | Patient temperature regulation method and apparatus |
| US6231594B1 (en) * | 1999-08-11 | 2001-05-15 | Radiant Medical, Inc. | Method of controlling body temperature while reducing shivering |
| CA2380524A1 (en) * | 1999-08-25 | 2001-03-01 | Barrett R. Cooper | Compositions and methods for treating opiate intolerance |
-
2003
- 2003-04-02 US US10/405,301 patent/US20040087606A1/en not_active Abandoned
- 2003-10-30 CA CA002517456A patent/CA2517456A1/en not_active Abandoned
- 2003-10-30 EP EP03781446A patent/EP1567153A4/en not_active Withdrawn
- 2003-10-30 JP JP2005502201A patent/JP2006504805A/en active Pending
- 2003-10-30 WO PCT/US2003/034317 patent/WO2004041171A2/en active Application Filing
- 2003-10-30 AU AU2003288954A patent/AU2003288954A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040087606A1 (en) | 2004-05-06 |
| AU2003288954A8 (en) | 2004-06-07 |
| EP1567153A4 (en) | 2010-06-02 |
| JP2006504805A (en) | 2006-02-09 |
| WO2004041171A2 (en) | 2004-05-21 |
| EP1567153A2 (en) | 2005-08-31 |
| WO2004041171A3 (en) | 2004-09-16 |
| AU2003288954A1 (en) | 2004-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7361186B2 (en) | Active body cooling with vasodilation to reduce body temperature | |
| US20040087606A1 (en) | Shivering suppression during cooling to lower body temperature | |
| Shukla et al. | A comparative study of the effect of clonidine and tramadol on post-spinal anaesthesia shivering | |
| Glosten et al. | Preanesthetic skin-surface warming reduces redistribution hypothermia caused by epidural block | |
| Panzer et al. | Shivering and shivering-like tremor during labor with and without epidural analgesia | |
| US10238533B2 (en) | Gastric, cutaneous, or peritoneal delivery of frozen mist to induce therapeutic hyperthermia | |
| Zweifler et al. | Induction and maintenance of mild hypothermia by surface cooling in non-intubated subjects | |
| Glosten et al. | Epidural anesthesia and the thermoregulatory responses to hyperthermia‐preliminary observations in volunteer subjects | |
| US20180289890A1 (en) | Volume adjustment infusion system and method | |
| Alfonsi et al. | Nefopam and alfentanil additively reduce the shivering threshold in humans whereas nefopam and clonidine do not | |
| US20180280620A1 (en) | Shivering adjustment infusion system and method | |
| Rozen et al. | Perioperative management of opioid-tolerant chronic pain patients | |
| Sarshivi et al. | Intravenous ketamine for the prevention of post anesthetic shivering in spinal anesthesia: A randomized double-blind placebo-controlled trial | |
| Kalil | Unintended subdural injection: a complication of epidural anesthesia--a case report. | |
| Cottle et al. | Maternal and fetal cardiovascular indices during fetal hypoxia due to cord compression in chronically cannulated sheep: I. Responses to timolol | |
| Wasson et al. | Epidural, Caudal, Spinal, Combined Spinal/Epidural | |
| Xie et al. | Observation and Analysis of the Postoperative Analgesic Effect of Subanaesthetic Dose of Ketamine in Kashin–Beck Disease Patients after Total Knee Arthroplasty | |
| Brooker et al. | Topical ice slurry prevents brain rewarming during deep hypothermic circulatory arrest in newborn sheep | |
| Irone et al. | Extracorporeal membrane oxygenation in emergency resuscitation from deep hypothermia | |
| Shannon et al. | An intravenous fluid bolus is not necessary before administration of intrathecal fentanyl for labor analgesia | |
| Suresh et al. | Comparison of intravenous butorphanol, ondansetron and tramadol for control of shivering during regional anesthesia: A prospective, randomized double-blind study. | |
| Hindman | Hypothermia in neurological and cardiac anethesia | |
| Varışlı | Hypothermia as a Medication Side Effect | |
| Wong et al. | Sedation and Analgesia for HIFU Ablation | |
| Madubuko et al. | Comparative Evaluation of Haemodynamic Effects of Continuous Versus Intermittent Epidural Injections of Bupivacaine with Fentanyl for Major Gynaecological Surgeries |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |